Compare Gilead Sciences, Inc. (GILD) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs M&T Bank Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.83 (market cap $163.51B), while M&T Bank Corporation trades at $253.32 (market cap $36.02B). The key difference: Gilead Sciences, Inc. is far larger — about 4.5× M&T Bank Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MTB | |
|---|---|---|
Market Cap | $163.51B | $36.02B |
Sector | Health | Financials |
52-Week High | $155.80 | $248.53 |
52-Week Low | $108.22 | $178.63 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
M&T Bank (MTB) trades at $253.23, up 4.71% on strong Q2 2026 earnings that beat expectations with EPS of $5.35 versus $4.66 estimates. The stock shows bullish technical momentum with price above key resistance levels, supported by solid fundamentals including a 30.11% net income margin and consistent earnings growth. Recent analyst coverage reflects cautious optimism with 29% buy ratings amid a predominantly hold consensus.
MTB presents a balanced investment case with strong profitability and dividend yield, though near-term risks include declining operating cash flow and elevated debt levels. The stock trades at a reasonable P/E of 13.16, offering value relative to earnings growth potential, but investors should monitor net interest income trends and credit quality amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
